1
|
Swope K, Morton J, Pogue GP, Burden L, Partain N, Hume S, Shepherd J, Simpson CA, Brennan MB, Furman TC, Kingrey-Gebe S, Martinez T, McDonough J, Pauly MH, Whaley KJ, Zeitlin L, Bratcher B, Haydon H. Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana. MAbs 2022; 14:2013594. [PMID: 35000569 PMCID: PMC8744878 DOI: 10.1080/19420862.2021.2013594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 11/12/2021] [Accepted: 11/19/2021] [Indexed: 10/24/2022] Open
Abstract
The ongoing SARS-CoV-2 coronavirus pandemic of 2020-2021 underscores the need for manufacturing platforms that can rapidly produce monoclonal antibody (mAb) therapies. As reported here, a platform based on Nicotiana benthamiana produced mAb therapeutics with high batch-to-batch reproducibility and flexibility, enabling production of 19 different mAbs of sufficient purity and safety for clinical application(s). With a single manufacturing run, impurities were effectively removed for a representative mAb product (the ZMapp component c4G7). Our results show for the first time the reproducibility of the platform for production of multiple batches of clinical-grade mAb, manufactured under current Good Manufacturing Practices, from Nicotiana benthamiana. The flexibility of the system was confirmed by the results of release testing of 19 different mAbs generated with the platform. The process from plant infection to product can be completed within 10 days. Therefore, with a constant supply of plants, response to the outbreak of an infectious disease could be initiated within a matter of weeks. Thus, these data demonstrated that this platform represents a reproducible, flexible system for rapid production of mAb therapeutics to support clinical development.
Collapse
MESH Headings
- Antibodies, Monoclonal/biosynthesis
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/genetics
- Antibodies, Monoclonal/immunology
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/chemistry
- Antibodies, Viral/genetics
- Antibodies, Viral/immunology
- COVID-19/immunology
- Humans
- Plants, Genetically Modified/chemistry
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/growth & development
- Plants, Genetically Modified/immunology
- Recombinant Proteins/biosynthesis
- Recombinant Proteins/chemistry
- Recombinant Proteins/genetics
- Recombinant Proteins/immunology
- SARS-CoV-2/immunology
- Nicotiana/chemistry
- Nicotiana/genetics
- Nicotiana/growth & development
- Nicotiana/immunology
- COVID-19 Drug Treatment
Collapse
Affiliation(s)
- Kelsi Swope
- Kentucky BioProcessing, Inc, Owensboro, KY, USA
| | - Josh Morton
- Kentucky BioProcessing, Inc, Owensboro, KY, USA
| | - Gregory P. Pogue
- Kentucky BioProcessing, Inc, Owensboro, KY, USA
- IC Institute, the University of Texas at Austin, Austin, TXUSA
| | | | | | - Steve Hume
- Kentucky BioProcessing, Inc, Owensboro, KY, USA
| | | | | | | | | | | | | | | | | | - Kevin J. Whaley
- ZabBio, Inc, San Diego, CA, USA
- Mapp Biopharmaceutical, Inc, San Diego, Ca, USA
| | - Larry Zeitlin
- ZabBio, Inc, San Diego, CA, USA
- Mapp Biopharmaceutical, Inc, San Diego, Ca, USA
| | | | - Hugh Haydon
- Kentucky BioProcessing, Inc, Owensboro, KY, USA
| |
Collapse
|
2
|
Swope K, Morton J, Pogue GP, Hume S, Pauly MH, Shepherd J, Simpson CA, Bratcher B, Whaley KJ, Zeitlin L, Davis KR, Haydon H. Manufacturing plant-made monoclonal antibodies for research or therapeutic applications. Methods Enzymol 2021; 660:239-263. [PMID: 34742392 DOI: 10.1016/bs.mie.2021.05.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Monoclonal antibodies (mAbs) hold great promise for treating diseases ranging from cancer to infectious disease. Manufacture of mAbs is challenging, expensive, and time-consuming using mammalian systems. We describe detailed methods used by Kentucky BioProcessing (KBP), a subsidiary of British American Tobacco, for producing high quality mAbs in a Nicotiana benthamiana host. Using this process, mAbs that meet GMP standards can be produced in as little as 10 days. Guidance for using individual plants, as well as detailed methods for large-scale production, are described. These procedures enable flexible, robust, and consistent production of research and therapeutic mAbs.
Collapse
Affiliation(s)
- Kelsi Swope
- Kentucky BioProcessing, Inc., Owensboro, KY, United States.
| | - Josh Morton
- Kentucky BioProcessing, Inc., Owensboro, KY, United States
| | | | - Steve Hume
- Kentucky BioProcessing, Inc., Owensboro, KY, United States
| | | | - John Shepherd
- Kentucky BioProcessing, Inc., Owensboro, KY, United States
| | | | - Barry Bratcher
- Kentucky BioProcessing, Inc., Owensboro, KY, United States
| | - Kevin J Whaley
- ZabBio, Inc., San Diego, CA, United States; Mapp Biopharmaceutical, Inc., San Diego, CA, United States
| | - Larry Zeitlin
- ZabBio, Inc., San Diego, CA, United States; Mapp Biopharmaceutical, Inc., San Diego, CA, United States
| | | | - Hugh Haydon
- Kentucky BioProcessing, Inc., Owensboro, KY, United States
| |
Collapse
|
3
|
Klimyuk V, Pogue G, Herz S, Butler J, Haydon H. Production of recombinant antigens and antibodies in Nicotiana benthamiana using 'magnifection' technology: GMP-compliant facilities for small- and large-scale manufacturing. Curr Top Microbiol Immunol 2014; 375:127-54. [PMID: 22527176 DOI: 10.1007/82_2012_212] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
This review describes the adaptation of the plant virus-based transient expression system, magnICON(®) for the at-scale manufacturing of pharmaceutical proteins. The system utilizes so-called "deconstructed" viral vectors that rely on Agrobacterium-mediated systemic delivery into the plant cells for recombinant protein production. The system is also suitable for production of hetero-oligomeric proteins like immunoglobulins. By taking advantage of well established R&D tools for optimizing the expression of protein of interest using this system, product concepts can reach the manufacturing stage in highly competitive time periods. At the manufacturing stage, the system offers many remarkable features including rapid production cycles, high product yield, virtually unlimited scale-up potential, and flexibility for different manufacturing schemes. The magnICON system has been successfully adaptated to very different logistical manufacturing formats: (1) speedy production of multiple small batches of individualized pharmaceuticals proteins (e.g. antigens comprising individualized vaccines to treat NonHodgkin's Lymphoma patients) and (2) large-scale production of other pharmaceutical proteins such as therapeutic antibodies. General descriptions of the prototype GMP-compliant manufacturing processes and facilities for the product formats that are in preclinical and clinical testing are provided.
Collapse
Affiliation(s)
- Victor Klimyuk
- Icon Genetics, Weinbergweg 22, 06120, Halle (Saale), Germany,
| | | | | | | | | |
Collapse
|
4
|
Mallajosyula JK, Hiatt E, Hume S, Johnson A, Jeevan T, Chikwamba R, Pogue GP, Bratcher B, Haydon H, Webby RJ, McCormick AA. Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge. Hum Vaccin Immunother 2013; 10:586-95. [PMID: 24378714 DOI: 10.4161/hv.27567] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Recombinant subunit vaccines are an efficient strategy to meet the demands of a possible influenza pandemic, because of rapid and scalable production. However, vaccines made from recombinant hemagglutinin (HA) subunit protein are often of low potency, requiring high dose or boosting to generate a sustained immune response. We have improved the immunogenicity of a plant-made HA vaccine by chemical conjugation to the surface of the Tobacco mosaic virus (TMV) which is non infectious in mammals. We have previously shown that TMV is taken up by mammalian dendritic cells and is a highly effective antigen carrier. In this work, we tested several TMV-HA conjugation chemistries, and compared immunogenicity in mice as measured by anti-HA IgG titers and hemagglutination inhibition (HAI). Importantly, pre-existing immunity to TMV did not reduce initial or boosted titers. Further optimization included dosing with and without alum or oil-in water adjuvants. Surprisingly, we were able to stimulate potent immunogenicity and HAI titers with a single 15 µg dose of HA as a TMV conjugate. We then evaluated the efficacy of the TMV-HA vaccine in a lethal virus challenge in mice. Our results show that a single dose of the TMV-HA conjugate vaccine is sufficient to generate 50% survival, or 100% survival with adjuvant, compared with 10% survival after vaccination with a commercially available H1N1 vaccine. TMV-HA is an effective dose-sparing influenza vaccine, using a single-step process to rapidly generate large quantities of highly effective flu vaccine from an otherwise low potency HA subunit protein.
Collapse
Affiliation(s)
| | - Ernie Hiatt
- Kentucky BioProcessing LLC; Owensboro, KY USA
| | - Steve Hume
- Kentucky BioProcessing LLC; Owensboro, KY USA
| | | | | | - Rachel Chikwamba
- Council for Scientific and Industrial Research; Pretoria, South Africa
| | - Gregory P Pogue
- Kentucky BioProcessing LLC; Owensboro, KY USA; IC2 Institute; The University of Texas at Austin; Austin, TX USA
| | | | - Hugh Haydon
- Kentucky BioProcessing LLC; Owensboro, KY USA
| | | | | |
Collapse
|
5
|
Ma JKC, Christou P, Chikwamba R, Haydon H, Paul M, Ferrer MP, Ramalingam S, Rech E, Rybicki E, Wigdorovitz A, Yang DC, Thangaraj H. Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies. Plant Biotechnol J 2013; 11:1029-33. [PMID: 24119183 DOI: 10.1111/pbi.12127] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Revised: 07/31/2013] [Accepted: 09/03/2013] [Indexed: 05/20/2023]
Abstract
Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might be used to improve access to modern medicines, and improve health of the poor in developing countries and emerging economies. Although improving global health through molecular pharming has been discussed for at least two decades, little progress has actually been made. In this manuscript, a four point plan is described to maximise the opportunity for molecular pharming to provide solutions. These are (i) to identify and prioritise important drug targets that are relevant to the poor; (ii) to support research and development partners in low to middle income countries to develop local expertise, transfer technology and build capacity; (iii) to increase collaboration between regulatory bodies to enable national regulatory frameworks to be developed in low to middle income countries; and (iv) to promote intellectual property management approaches that include socially responsible licensing. An existing case study is described to illustrate how this might be achieved.
Collapse
Affiliation(s)
- Julian K-C Ma
- The Hotung Molecular Immunology Unit, Division of Clinical Sciences, St. George's University of London, London, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Pogue GP, Vojdani F, Palmer KE, Hiatt E, Hume S, Phelps J, Long L, Bohorova N, Kim D, Pauly M, Velasco J, Whaley K, Zeitlin L, Garger SJ, White E, Bai Y, Haydon H, Bratcher B. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 2010; 8:638-54. [PMID: 20514694 DOI: 10.1111/j.1467-7652.2009.00495.x] [Citation(s) in RCA: 107] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Plants have been proposed as an attractive alternative for pharmaceutical protein production to current mammalian or microbial cell-based systems. Eukaryotic protein processing coupled with reduced production costs and low risk for mammalian pathogen contamination and other impurities have led many to predict that agricultural systems may offer the next wave for pharmaceutical product production. However, for this to become a reality, the quality of products produced at a relevant scale must equal or exceed the predetermined release criteria of identity, purity, potency and safety as required by pharmaceutical regulatory agencies. In this article, the ability of transient plant virus expression systems to produce a wide range of products at high purity and activity is reviewed. The production of different recombinant proteins is described along with comparisons with established standards, including high purity, specific activity and promising preclinical outcomes. Adaptation of transient plant virus systems to large-scale manufacturing formats required development of virus particle and Agrobacterium inoculation methods. One transient plant system case study illustrates the properties of greenhouse and field-produced recombinant aprotinin compared with an US Food and Drug Administration-approved pharmaceutical product and found them to be highly comparable in all properties evaluated. A second transient plant system case study demonstrates a fully functional monoclonal antibody conforming to release specifications. In conclusion, the production capacity of large quantities of recombinant protein offered by transient plant expression systems, coupled with robust downstream purification approaches, offers a promising solution to recombinant protein production that compares favourably to cell-based systems in scale, cost and quality.
Collapse
|